Skip Navigation

Cardiovascular Research 2003 60(2):388-396; doi:10.1016/j.cardiores.2003.07.001
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Flavigny, J.
Right arrow Articles by Berrebi-Bertrand, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flavigny, J.
Right arrow Articles by Berrebi-Bertrand, I.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Biomolecular interactions between human recombinant β-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy

Jeanne Flavignya,1, Philippe Robertb,1, Jean-Claude Camelinb, Ketty Schwartza, Lucie Carrier*,a and Isabelle Berrebi-Bertrandb

aINSERM U582, Institut de Myologie, Bâtiment Babinski, CHU Pitié-Salpêtrière, 47 Bld de l'Hôpital, 75651 Paris Cedex 13, France
bLaboratoires GlaxoSmithKline, Saint-Grégoire, France

*Corresponding author. Tel.: +33-1-42-16-57-15; fax: +33-1-42-16-57-00. Email address: l.carrier{at}myologie.chups.jussieu.fr

Objective: Cardiac myosin-binding protein C (cMyBP-C) is a component of sarcomere that contains at least three putative myosin-binding sites. Mutations in its gene are implicated in familial hypertrophic cardiomyopathy (FHC) and most of them are predicted to produce C-terminal truncated cMyBP-Cs. The aim of the present study was to analyze whether cMyBP-C truncated mutants resulting from FHC mutations interact in vitro with human β-MyHC. Methods: Recombinant proteins were produced using the baculovirus/insect cell system, and wild type and three truncated cMyBP-Cs were purified using metal affinity chromatography. The interaction between recombinant proteins was analyzed in real time using biosensor technology on immobilized anti-β-MyHC antibodies. Results: Biomolecular interaction with β-MyHC was detected for both wild type cMyBP-C and a truncated mutant lacking half of the C-terminal C10 domain. In contrast, no interaction with β-MyHC was found for two truncated cMyBP-Cs lacking at least the C5–C9 region. Conclusions: Biosensor technology allows in vitro analysis of the interaction between human β-MyHC and cMyBP-C mutants resulting from FHC mutations. The data show that the interaction depends on the size of the truncation. This suggests that, in the context of FHC, impairment of suitable interaction between β-MyHC and some of the truncated cMyBP-Cs may promote degradation of the truncated proteins and therefore contribute to the development of the disease.

KEYWORDS Cardiomyopathy; Contractile apparatus; Hypertrophy; Biosensors


1 Contributed equally to this work.

Time for primary review 28 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
L. Carrier, S. Schlossarek, M. S. Willis, and T. Eschenhagen
The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy
Cardiovasc Res, January 15, 2010; 85(2): 330 - 338.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
N. Vignier, S. Schlossarek, B. Fraysse, G. Mearini, E. Kramer, H. Pointu, N. Mougenot, J. Guiard, R. Reimer, H. Hohenberg, et al.
Nonsense-Mediated mRNA Decay and Ubiquitin-Proteasome System Regulate Cardiac Myosin-Binding Protein C Mutant Levels in Cardiomyopathic Mice
Circ. Res., July 31, 2009; 105(3): 239 - 248.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
J. L. Theis, J. M. Bos, J. D. Theis, D. V. Miller, J. A. Dearani, H. V. Schaff, B. J. Gersh, S. R. Ommen, R. L. Moss, and M. J. Ackerman
Expression Patterns of Cardiac Myofilament Proteins: Genomic and Protein Analysis of Surgical Myectomy Tissue From Patients With Obstructive Hypertrophic Cardiomyopathy
Circ Heart Fail, July 1, 2009; 2(4): 325 - 333.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. Pohlmann, I. Kroger, N. Vignier, S. Schlossarek, E. Kramer, C. Coirault, K. R. Sultan, A. El-Armouche, S. Winegrad, T. Eschenhagen, et al.
Cardiac Myosin-Binding Protein C Is Required for Complete Relaxation in Intact Myocytes
Circ. Res., October 26, 2007; 101(9): 928 - 938.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Sarikas, L. Carrier, C. Schenke, D. Doll, J. Flavigny, K. S. Lindenberg, T. Eschenhagen, and O. Zolk
Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants
Cardiovasc Res, April 1, 2005; 66(1): 33 - 44.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
T. P. V. Manh, M. Mokrane, E. Georgenthum, J. Flavigny, L. Carrier, M. Semeriva, M. Piovant, and L. Roder
Expression of cardiac myosin-binding protein-C (cMyBP-C) in Drosophila as a model for the study of human cardiomyopathies
Hum. Mol. Genet., January 1, 2005; 14(1): 7 - 17.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Carrier, R. Knoll, N. Vignier, D. I Keller, P. Bausero, B. Prudhon, R. Isnard, M.-L. Ambroisine, M. Fiszman, J. Ross Jr., et al.
Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice
Cardiovasc Res, August 1, 2004; 63(2): 293 - 304.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.